We are Deciphera, a Member of the Ono Group
We are a commercial-stage company on a mission to develop and deliver breakthrough medicines to patients. Headquartered in Waltham, MA with research facilities in Lawrence, KS, Deciphera is leading Ono Pharma’s expansion in the U.S. and Europe with a robust pipeline of clinical programs with first- or best-in-class potential.
Inspired by Patients
Every breakthrough begins with a patient story. From our earliest target identification to our post-approval support, Deciphera is united by a shared commitment to understand and improve the lives of those we serve. We are dedicated. We are focused. We are motivated.
A Diverse Pipeline
We are developing a diverse pipeline of medicines across oncology, neurology, immunology & inflammation to make a meaningful difference in patients’ lives.
>450
Global Employees
12+
Countries
2
Marketed Products
Deciphera was founded in 2003 in Lawrence, Kansas, with the goal of establishing an infrastructure and culture that nurtured true innovation, inspiration, and results. We set a standard for ethics and accountability, which is still evident today in our values.
Deciphera completed its initial public offering and became publicly listed on Nasdaq as DCPH.
The FDA granted marketing authorization for Deciphera’s QINLOCK® (ripretinib). The approvals in the UK and Europe were granted in 2021.
Deciphera established European operations with the formation of Deciphera Pharmaceuticals AG. Headquartered in Switzerland, with offices in Germany, Spain, France, Italy and the Netherlands.
Deciphera became a proud member of Ono Pharma.
The FDA granted marketing authorization for Deciphera’s ROMVIMZA® (vimseltinib). The approval by the European Commission came later that same year.
